At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Vorinostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients
In Brief
A Phase 2 clinical trial evaluating Vorinostat and Bevacizumab for Recurrent Glioblastoma Multiforme and 2 related conditions. Completed, enrolled 48 participants across 1 site.
Detailed Summary
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both chemotherapy and anti-angiogenics. Patients will be treated with a combination of bevacizumab and vorinostat.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGenentech, Inc., Merck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartJan 2013
Primary CompletionDec 2014
Study CompletionFeb 2016
TodayJul 2026
First PostedNov 30, 2012
Enrollment StartJan 1, 2013
Primary CompletionDec 1, 2014
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.6 years ago
Interventions
Vorinostatdrug
Bevacizumabdrug